trending Market Intelligence /marketintelligence/en/news-insights/trending/x2_QOKc8qAymGGvot8IlQg2 content esgSubNav
In This List

China approves launch of Roche's Perjeta for breast cancer

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


China approves launch of Roche's Perjeta for breast cancer

China's National Medical Products Administration approved the importation of Roche Holding AG's Perjeta as a treatment for HER2-positive breast cancer, in combination with Herceptin and chemotherapy.

Perjeta, also known as pertuzumab, works by preventing the human epidermal growth factor receptor 2, or HER2, from pairing with other HER receptors on the surface of cancer cells. Binding of Perjeta to HER2 may also signal the immune system to destroy cancer cells.

Herceptin, also marketed by Roche, was included in China's national drug reimbursement list in 2017.

SNL Image